Table 1.

Summary of cardiovascular risk assessment for patients with rheumatoid arthritis

Risk factor	boDMARD								tsDMARD
	ABA	ADA	ETN	GLM	INF	RTX	SEC	TCZ	TOFA
TC	↔	↔	↑		↑	↑/↔	↔	↑	↑
HDL-C	↑/↔	↑/↔	↑		↑	↑/↔	↔	↑	↑
LDL-C	↑/↔	↑/↔	↔		↑/↔	↔	↔	↑	↑
TG	↔	↔	↔		↑	↔		↑	↑
Atherogenic index	↔	↔			↑/↔/↓	↑/↔	↔	↓	↔
ApoB:ApoA-1		↔	↓				↔	↓	↔
Systolic BP	↔	↔	↔		↔	↔		↔
Diastolic BP	↔	↔			↔
CAVI	↔	↓	↓					↓
Augmentation index	↔	↓	↓		↑/↔	↔		↓
cIMT	↔	↔			↔	↓		↔
CRP	↓/↔	↓	↓		↓	↓/↔		↓	↓
sPLA2		↓						↓
SAA		↓						↓
MI		0.3–0.6%	0.8%		0.2%			0.6%
Stroke		0.3%						0.3%
Carotid artery plaque	↔							↔
FMD		↑
Rate of CV SAEs per 100 PY				0.25–0.43
Adjusted HRa	1.0–1.6	0.8–1.8	1.8		1.1–1.3	0.98–2.4		0.37

Blank cells indicate that data were not reported in original publications

ABA abatacept, ADA adalimumab, Apo apolipoprotein, boDMARD biological originator disease-modifying anti-rheumatic drug, BP blood pressure, CAVI cardio-ankle vascular index, cIMT carotid inter-media thickness, CRP C-reactive protein, CV cardiovascular, ETN etanercept, FMD flow-mediated dilation, GLM golimumab, HDL-C high-density lipoprotein cholesterol, HR hazard ratio, INF infliximab, LDL-C low-density lipoprotein cholesterol, MI myocardial infarction, PY person-years, RTX rituximab, SAA serum amyloid A, SAE serious adverse event, SEC secukinumab, sPLA2 secretory phospholipase A₂, TC total cholesterol, TCZ tocilizumab, TG triglycerides, TOFA tofacitinib, tsDMARD targeted synthetic disease-modifying anti-rheumatic drug, ↑ significantly increased, ↓ significantly decreased, ↔ no significant effect

^aRelative to the comparator in that study